Dermira, a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced that it has completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital and other healthcare investors, in the transaction. Leerink Partners LLC acted as the exclusive placement agent for the financing. Fenwick & West LLP acted as legal advisor to Dermira.

Dermira also announced key executive appointments with Andrew Guggenhime as Chief Operating Officer and Chief Financial Officer, Christine Conroy as Senior Vice President, Regulatory Affairs and Christine Ring as Vice President, Legal. In addition, Dermira has expanded its board of directors with the appointments of Dr. David E. Cohen, Matthew Fust, Mark McDade and William Ringo.

About Dermira

Dermira is a privately held specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates, Cimzia (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis, DRM04, a topical treatment for hyperhidrosis, and DRM01, a topical sebum inhibitor for the treatment of acne. Dermira is headquartered in Redwood City, California. For more information, please visit www.dermira.com.